Endoscopic Ultrasound-guided Radiofrequency Ablation of Pancreatic Cysts (ERASE) (ERASE)
Pancreatic Cyst, Radiofrequency Ablation
About this trial
This is an interventional treatment trial for Pancreatic Cyst focused on measuring ablation of neoplastic pancreatic cysts
Eligibility Criteria
Inclusion Criteria: Age >18 years. A diagnosis of a PCN confirmed by EUS-FNA including cyst fluid NGS and/or EUS-nCLE and/or EUS-TTNB (through the needle biopsy). The PCL measures at least 2 cm in diameter on either CT or MRI/MRCP or EUS and demonstrates concerning worrisome and/or high-risk features as defined by International Consensus Guidelines (2017 revised Fukuoka Guidelines). The patient is not a surgical candidate after consultation with Hepato-Pancreato-Biliary (HPB) surgery and/or review in the pancreatic multi-disciplinary tumor board conference. Common clinical scenarios include - Cirrhosis of the liver (common clinical scenario) Advanced age (common clinical scenario) Morbid obesity Significant cardiorespiratory comorbidity Patient's choice (patient elects for non-surgical management) Other significant comorbid conditions that impose prohibitive surgical risks Estimated life expectancy of at least 1 year. Capable of giving written informed consent. Women of childbearing potential must have a negative pregnancy test (serum/urine) on the day of treatment. Pregnancy testing is the routine standard of care practice in the endoscopy laboratory for all patients undergoing endoscopy and sedation for endoscopy. The patient prefers non-surgical management after consultation with Hepato-Pancreato-Biliary (HPB) surgery The patient is not a surgical candidate and has had prior attempts at ablation of the PCN by EUS-guided injection of chemotherapy (OSU IRB protocol 2020C0198) Exclusion Criteria: A diagnosis of a benign or non-neoplastic PCL such as a pseudocyst confirmed by EUS-FNA including cyst fluid NGS and/or EUS-nCLE and/or EUS-TTNB. A diagnosis of a malignant PCN confirmed by evidence of adenocarcinoma and/or invasive carcinoma and/or distant metastases Cysts or NETS (neuroendocrine tumors) involving or in close proximity to blood vessels or the biliary tree where the zone of ablation is likely to compromise these structures. PCNs such as IPMNs involving the main pancreatic duct as in mixed-IPMN lesions. Acute pancreatitis in the preceding 4 weeks prior to date of EUS-RFA Any evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it unsafe for the patient to participate in the study. Any psychiatric disorder making reliable informed consent impossible. Pregnancy or breast-feeding. ECOG performance status 4. Contraindication to general anesthesia after review by OSU Preoperative Assessment Clinic (OPAC) Cardiac Implantable Electrical Devices
Sites / Locations
- The Ohio State University Wexner Medical CenterRecruiting
Arms of the Study
Arm 1
Other
EUS-guided radiofrequency ablation of pancreatic cystic lesion(s)
Single arm study. EUS-guided intervention with radiofrequency ablation of pancreatic cystic lesions. Primary population of interest: Branch duct IPMN (intraductal papillary mucinous neoplasm) with high-risk for surgical intervention. The intervention is performed using an FDA-cleared device (EUS-RFA probe).